How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,976 results for

Serum Ferritin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

5721. Iron supplementation for acute blood loss anemia after coronary artery bypass surgery: a randomized, placebo-controlled study. (Abstract)

these values increased equally for all groups to a mean for the cohort of 13.6 +/- 1 gm/dl for hemoglobin and 40.6% +/- 3 for hematocrit. Serum iron and ferritin were within the normal range. The 200 mg group experienced significantly more side effects (p < 0.01).Thus the use of oral iron supplements for the treatment of acute blood loss anemia after uncomplicated coronary artery bypass surgery did not assist in restoring red blood cell mass or help maintain total body iron stores. (...) for elective coronary artery bypass surgery over a consecutive 8-month period.Before surgery: serum iron, serum ferritin, hemoglobin and hematocrit. Six days after surgery: hemoglobin and hematocrit. Mean of 59 days after surgery: serum iron, serum ferritin, hemoglobin and hematocrit.Patients were randomized to one of four groups: control group; placebo group; low-dose group, 50 mg elemental iron + 60 mg ascorbic acid in a multi-vitamin daily; and usual-dose group, 200 mg elemental iron daily.One hundred

1995 Heart & Lung Controlled trial quality: uncertain

5722. Side effects of iron supplements in blood donors: superior tolerance of heme iron. (Abstract)

Side effects of iron supplements in blood donors: superior tolerance of heme iron. Regular blood donors were enrolled in a double-blind, parallel group study to evaluate the side effects of two iron supplements, one containing both heme iron and non-heme iron (Hemofer, 2 tablets = 18 mg iron/day), the other non-heme iron only (Erco-Fer; 1 tablet = 60 mg iron/day). No differences were found between the two alternatives in regaining predonation iron status as measured by serum ferritin

1994 The Journal of laboratory and clinical medicine Controlled trial quality: uncertain

5723. Erythropoietic activity and iron metabolism in autologous blood donors during recombinant human erythropoietin therapy. (Abstract)

expressed as serum transferrin receptor concentration (sTfR) showed a 4-fold increase from 3.8 +/- 0.9 micrograms ml-1 to 14.9 +/- 4.8 micrograms ml-1 in the epo group. Effective erythropoietic activity measured by absolute reticulocyte count, however, declined after the fourth rhEPO injection in the epo group. Serum ferritin was lower in the epo group, but no differences in serum iron, transferrin concentration and transferrin saturation were observed between the groups. A marked increase in free (...) Erythropoietic activity and iron metabolism in autologous blood donors during recombinant human erythropoietin therapy. The use of recombinant human erythropoietin (rhEPO) to intensify the erythropoietic response in autologous donors may reduce homologous blood requirement. We studied the effect of subcutaneous rhEPO (500 U kg-1 body weight twice weekly during a 3 week period) on variables of erythropoiesis and iron metabolism in 62 autologous blood donors, of whom 32 received rhEPO (epo group

1994 European journal of clinical investigation Controlled trial quality: uncertain

5724. Long-term blood cholesterol-lowering effects of a dietary fiber supplement. (Abstract)

Long-term blood cholesterol-lowering effects of a dietary fiber supplement. The study evaluated the blood cholesterol-lowering effects of a dietary supplement of water-soluble fibers (guar gum, pectin) and mostly non-water-soluble fibers (soy fiber, pea fiber, corn bran) in subjects with mild to moderate hypercholesterolemia (LDL cholesterol, 3.37-4.92 mmol/L).After stabilization for 9 weeks on a National Cholesterol Education Program Step 1 Diet, subjects were randomly assigned to receive 20 g (...) ), triglyceride, iron, ferritin, or vitamin A or E levels. Similar effects were seen over the subsequent 36-week noncomparative part of the study.The fiber supplement provided significant and sustained reductions in LDL-C without reducing HDL-C or increasing triglycerides over the 51-week treatment period.

1999 American journal of preventive medicine Controlled trial quality: uncertain

5725. The effect of blood transfusion protocol on retinopathy of prematurity: A prospective, randomized study. (Abstract)

were divided randomly into two groups beginning on day of life 29. Group 1 (n = 24) received red cell transfusions during the 6-week study period, only if certain symptom-based guidelines were met. Group 2 (n = 26) received red cell transfusions to maintain the hematocrit level above 40% for the entire 6 weeks. Infants were monitored for ROP, growth, and associated morbidity. Serial measurements of serum glucose, lactate, ferritin, total iron-binding capacity, and iron were performed.ROP occurred (...) The effect of blood transfusion protocol on retinopathy of prematurity: A prospective, randomized study. Controversy exists regarding the potential influence of anemia and blood transfusions on the rate of retinopathy of prematurity (ROP) in premature infants. A prospective, randomized, masked trial was performed to determine the influence of red blood cell transfusion protocol on ROP incidence and severity in a population of high-risk infants.A total of 50 infants with birth weights <1251 g

1999 Pediatrics Controlled trial quality: uncertain

5726. Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. (Abstract)

hematocrit value less than 0.42, and in those aged > or = 60 years. The iron supplementation proved adequate despite the fact that a significant decrease in ferritin (median, 48.1%) and transferrin saturation (median, 40.5%) was observed in epoetin beta patients preoperatively. No influence of epoetin beta therapy on blood pressure, laboratory safety variables, or the frequency of specific adverse events was observed. Intravenous epoetin beta treatment of 5 x 500 U/kg BW in combination with 300 mg Fe2 (...) Avoidance of allogeneic blood transfusions by treatment with epoetin beta (recombinant human erythropoietin) in patients undergoing open-heart surgery. In a double-blind, randomized, placebo-controlled trial, we evaluated the ability of epoetin beta (recombinant human erythropoietin) to avoid allogeneic blood transfusions (ABT) and the associated risks in patients undergoing primary elective open-heart surgery and in whom autologous blood donation (ABD) was contraindicated. Seventy-six patients

1997 Blood Controlled trial quality: predicted high

5727. The effect of low-dose 3-keto-desogestrel added to a copper-releasing intrauterine contraceptive device on menstrual blood loss: a double-blind, dose-finding, placebo-controlled study. (Abstract)

healthy women with or without menorrhagia were enrolled and randomized to four different Multiload Cu250 intrauterine contraceptive devices, releasing 0 (control), 1.5, 3, or 6 microg of 3-keto-desogestrel daily. Menstrual blood loss, hemoglobin, and serum ferritin levels were determined before and during treatment.All 3-keto-desogestrel-copper intrauterine contraceptive devices reduced menstrual blood loss significantly, causing a reduction of up to 30 to 40 mL after 12 months of use. All women (...) with essential menorrhagia were considered to have been successfully treated after 6 months of use. Serum ferritin levels rose with all three 3-keto-desogestrel-loaded devices.A Multiload Cu250 intrauterine contraceptive device releasing 1.5 microg of 3-keto-desogestrel daily is able to reduce menstrual blood loss to a very low level and to replete body iron stores in women with or without menorrhagia. Higher doses have no superior effect.

2000 American journal of obstetrics and gynecology Controlled trial quality: uncertain

5728. Effects of iron repletion on blood volume and performance capacity in young athletes. (Abstract)

Effects of iron repletion on blood volume and performance capacity in young athletes. The purpose of this study was to find out whether iron repletion leads to an increase in red blood cell volume (RBV) and performance capacity in iron-deficient nonanemic athletes.40 young elite athletes (13-25 yr) with low serum ferritin (< 20 microg.L-1) and normal hemoglobin (males > 13.5 g.dL-1, females > 11.7 g.dL-1) were randomly assigned to 12-wk treatment with either twice a day ferrous iron (equivalent (...) to 2 x 100 mg elemental iron) or with placebo using a double blind method. Before and after treatment, hematological measures and parameters of iron status were determined in venous blood. RBV, blood volume (BV), and plasma volume (PV) were measured by CO rebreathing. For determination of the aerobic and anaerobic capacity (maximal accumulated oxygen deficit, MAOD), the athletes performed an incremental as well as a highly intensive treadmill test.After 12 wk, ferritin levels were within the normal

2001 Medicine and science in sports and exercise Controlled trial quality: uncertain

5729. Elective coronary and valve surgery without blood transfusion in patients treated with recombinant human erythropoietin (epoetin-alpha). (Abstract)

B (30 patients) treated with epoetin-alpha 10,000 UI twice a week and 525 mg ferrous sulphate 3 times a day. Grouping of patients has been randomized. In both groups hemoglobin, hematocrit, reticulocytes, iron values, ferritine, transferrine, and serological values, have been evaluated sequentially before treatment, before surgery, day of operation, 1st, 2nd, 3rd, 7th postoperative days and at discharge.In group A 86% patients needed blood transfusion (26 out of 30); in group B only 3 (...) Elective coronary and valve surgery without blood transfusion in patients treated with recombinant human erythropoietin (epoetin-alpha). This study evaluates the real effectiveness of epoetin-alpha associated with ferrous sulphate, in reducing blood transfusion in patients undergoing elective open heart surgery not treated with autologous donation.Sixty patients had been divided into 2 groups: group A (30 patients) treated with 525 mg ferrous sulphate three time a day per os for 3 weeks; group

2000 Minerva cardioangiologica Controlled trial quality: uncertain

5730. Psychosocial and other characteristics of women complaining of menorrhagia, with and without actual increased menstrual blood loss. (Abstract)

psychosocial factors, seeking medical attention, menstrual blood loss.Twenty-nine percent of the women had their menstrual blood loss in the normal range (menstrual blood loss <60 mL). By univariate analysis, unemployment, anxiety, perceived inconvenience, abdominal pain, haemoglobin level and serum ferritin concentration distinguished this group of women from those with true menorrhagia. Unemployment, perceived inconvenience, abdominal pain and serum ferritin remained significant variables by multivariate (...) Psychosocial and other characteristics of women complaining of menorrhagia, with and without actual increased menstrual blood loss. To discover whether psychosocial factors can explain why many women with normal menstrual blood loss seek care for menorrhagia.Cross-sectional comparative study of women referred for menorrhagia.Gynaecology departments of all five university teaching hospitals in Finland.Two hundred and twenty-six women aged 35-49 years complaining of menorrhagia.Several

2001 BJOG Controlled trial quality: uncertain

5731. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. (Abstract)

was independent of morphologically detected bone marrow disease, MYCN status, and serum ferritin level in bivariate Cox analyses.Immunocytologic quantification of neuroblastoma cells in bone marrow and blood at diagnosis and in bone marrow during induction chemotherapy provides prognostic information that can identify patients with very high-risk disease who should be considered for experimental therapy that might improve outcome. (...) Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. This study investigated the prognostic value of quantifying tumor cells in bone marrow and blood by immunocytology in children with high-risk, metastatic neuroblastoma.Patients with stage IV neuroblastoma (N = 466) registered on Children's Cancer Group study 3891 received five cycles of induction chemotherapy and were randomized either to myeloablative

2000 Journal of clinical oncology : official journal of the American Society of Clinical Oncology Controlled trial quality: uncertain

5732. Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

decreased marrow erythroid precursors Positive marrow coculture with serum or cells or response to immunosuppression No evidence for PNH Negative Ham's test and sucrose hemolysis Severe disease: Chronic (i.e., greater than 1 year) Transfusion dependent or untransfused hemoglobin less than 8.0 g/dL Ferritin greater than 2,000 or evidence of organ dysfunction due to iron overload Refractory to conventional therapy after all 3 of the following: High dose steroids (at least 1 mg/kg) for at least 21 days (...) Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2000 Clinical Trials

5733. Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

, Layout table for eligibility information Ages Eligible for Study: 2 Years and older (Child, Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Age greater than or equal to 2 years Sickle cell disease patients already treated with or suitable for treatment with deferoxamine 20 to 40 mg/kg/day Serum ferritin greater than 1000 mg/ml Liver iron content greater than 2 mg iron/g dw assessed by means of superconducting quantum interference device (...) Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2003 Clinical Trials

5734. Comparison of Asymptomatic Carotid Atherosclerosis Between Frequent and Infrequent Blood Donors

: March 4, 2008 Last Verified: May 2002 Keywords provided by National Institutes of Health Clinical Center (CC): Ferritin Atherosclerosis Myocardial Infarction Blood Donors Low Density Lipoprotein Asymptomatic Carotid Atherosclerosis Additional relevant MeSH terms: Layout table for MeSH terms Infarction Myocardial Infarction Atherosclerosis Carotid Artery Diseases Ischemia Pathologic Processes Necrosis Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases Arteriosclerosis (...) Comparison of Asymptomatic Carotid Atherosclerosis Between Frequent and Infrequent Blood Donors Comparison of Asymptomatic Carotid Atherosclerosis Between Frequent and Infrequent Blood Donors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

1999 Clinical Trials

5735. Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron-deficient blood donors. (Abstract)

and 3 than in Group 2 (P < .01). However, body iron stores, reflected in serum ferritin level, was significantly better in Group 1 (P < .01); there was no difference in this respect between Groups 2 and 3.(ABSTRACT TRUNCATED AT 250 WORDS) (...) Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron-deficient blood donors. Absolute iron deficiency is treated by correcting the causative lesion and then, traditionally, administering sufficient amounts of ferrous salt to return the haemoglobin level to normal and replenish body stores. The bioavailability of ferric compounds has been questioned and accordingly their therapeutic role remains controversial. A special problem is posed by regular blood donation, where

1993 Journal of clinical apheresis Controlled trial quality: uncertain

5736. [Recombinant erythropoietin in autologous blood donation]. (Abstract)

blood withdrawal. All patients (n = 10) received oral iron therapy with iron sulphate 304 mg/die (= 100 mg iron/die). Patients with hypertension or recent myocardial infarction were excluded from the study. The hemoglobin level before donation had to be at least 11.0 g/dl. On each study day, a complete blood count and platelets, differential, and reticulocyte count were determined by standard methods as were transferrin, ferritin, and total iron-binding capacity. Blood loss and blood consumption (...) of autologous blood collection and before the onset of surgery, the number of reticulocytes was significantly greater in rHuEPO patients than in the controls. Further laboratory variables such as transferrin, ferritin, and total iron-binding capacity did not change significantly during the investigation period; there were no significant differences between the two groups. DISCUSSION. The results of the present study show that rHuEPO leads to an increase in reticulocytes with maintenance of hemoglobin levels

1991 Der Anaesthesist Controlled trial quality: uncertain

5737. The influence of copper surface area on menstrual blood loss and iron status in women fitted with an IUD. (Abstract)

fitted with a MLCu-375. An increase (p less than 0.01) in MBL was recorded 3 months after IUD insertion for both the women fitted with a MLCu-250 (86.4 +/- 10.3 ml) and a MLCu-375 (81.1 +/- 8.3 ml). This increase in MBL remained unchanged throughout the study period of one year. At no point were there any significant differences in MBL or increase in MBL between women fitted with a MLCu-250 or MLCu-375. There were no significant differences in serum ferritin, blood hemoglobin, hematocrit (...) The influence of copper surface area on menstrual blood loss and iron status in women fitted with an IUD. The influence of copper surface area on menstrual blood loss (MBL) was evaluated in 34 healthy women (mean age 36.4 +/- 1.4 yr, range 27-46 yr), who were fitted with a Multiload intrauterine device (IUD) with either 250 mm2 (MLCu-250) or 375 mm2 (MLCu-375) copper wire. MBL prior to IUD insertion was 54.4 +/- 10.3 ml for women subsequently fitted with a MLCu-250 and 56.9 +/- 6.9 ml for women

1990 Contraception Controlled trial quality: uncertain

5738. Effects of recombinant human erythropoietin on autologous blood donation before open heart surgery. (Abstract)

< 0.01). Although iron was supplied orally, ferritin levels declined in all groups whereas serum iron and transferrin levels remained unchanged. No influence could be detected on WBC, thrombocyte count, or arterial blood pressure. Mild and reversible side effects were observed in 8 patients (19%). Perioperatively 34 patients (81%) received exclusively autologous blood, only 8 patients (19%) needed additional homologous blood transfusions. Administration of high-dosed rhEPO (400-800 U/kg) seems (...) Effects of recombinant human erythropoietin on autologous blood donation before open heart surgery. We studied the effects of four different doses of recombinant human erythropoietin (rhEPO) on the amount of preoperative autologous blood donation. 43 patients prior to open heart surgery were randomized into 5 groups (100, 200, 400, 800 U/kg rhEPO i.v. or placebo) and treated twice weekly over a period of 4 weeks. Autologous blood was taken at a hemoglobin of 13 g/dl and a hematocrit of 34

1993 The Thoracic and cardiovascular surgeon Controlled trial quality: uncertain

5739. Effects of iron repletion on VO2max, endurance, and blood lactate in women. (Abstract)

Effects of iron repletion on VO2max, endurance, and blood lactate in women. To determine the effects of an 8-wk dietary iron supplementation (100 mg.d-1) on low plasma ferritin concentration (< 20 ng.ml-1) and endurance, 20 active women (19-35 yr) were studied while performing a VO2max test and an endurance test (80% VO2max) on a cycle ergometer. Subjects were randomly placed in an iron supplement (IG) or a placebo group (PG) using a double-blind method. After treatment in the IG, ferritin (...) levels were higher (22.5 +/- 3.4 vs 14.3 +/- 2.2 ng.ml-1; P < 0.05), Hb increased (12.8 +/- 0.4 to 14.1 +/- 0.2 g.dl-1; P < 0.05), and TIBC decreased (366.2 +/- 24.8 to 293.8 +/- 14.0 micrograms.dl-1; P < 0.05). Also after treatment the IG's VO2max was significantly greater (P < 0.05) than the PG value and their postendurance blood lactate decreased (5.03 +/- 0.44 to 3.85 +/- 0.6 mM.l-1; P < 0.05). Endurance time to exhaustion increased 38% (37.28 +/- 5.03 to 51.4 +/- 7.45 min) following iron

1993 Medicine and science in sports and exercise Controlled trial quality: uncertain

5740. Changes in blood manganese levels during pregnancy in iron supplemented and non supplemented women. (Abstract)

serum ferritin levels compared to the placebo group. No significant difference in blood manganese levels was observed among the three groups of women. There was a significant increase in blood manganese levels from one trimester to the next, which was slightly more pronounced in non supplemented women. The median values in the three trimesters were 154 (range 79-360) nmol/L, 190 (range 98-408) nmol/L, and 230 (range 133-481) nmol/L, respectively. Pregnancy seems to change manganese status (...) Changes in blood manganese levels during pregnancy in iron supplemented and non supplemented women. Blood manganese levels and iron status indices were determined each trimester in 66 healthy pregnant women. Twenty-five were randomly assigned to iron supplementation, 19 to placebo and 22 received dietary advise aimed at increasing their dietary intake of fibre. Iron supplemented women had significantly higher levels of blood haemoglobin compared to the levels of the two other groups, and higher

1995 Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>